About Xenetic Biosciences, Inc. - Common Stock (XBIO)
Xenetic Biosciences Inc is a biotechnology company focused on developing innovative drug delivery solutions and advanced therapies to treat a range of diseases. The company leverages its proprietary technologies, including its unique drug delivery platforms and biologics, to enhance the efficacy and safety of existing medications and to create new therapeutic options. By collaborating with pharmaceutical and biotechnology partners, Xenetic aims to address unmet medical needs and improve patient outcomes through its cutting-edge research and product development efforts. Read More
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the pricing of an underwritten offering of 735,000 shares of common stock at a price to the public of $6.12 per share, for gross proceeds of approximately $4.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All shares of common stock are being offered by Xenetic. The offering is expected to close on or about October 14, 2025, subject to the satisfaction of customary closing conditions.
Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam as the market rally broadens and major indexes continue to reach new highs. Here's a look at four stocks flashing strong momentum signals.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
In today’s MAGA Stocks Undercard lineup, a select group of small-cap innovators are reshaping the landscapes of social media, biotech, and blockchain technology. These companies—each positioned at the forefront of next-generation disruption—are demonstrating renewed investor confidence and sector-wide momentum heading into Q4.
Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies
Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date
- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.
